• 1
    Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 310.
  • 2
    Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-d-arabinofuranosylcytosine. Cancer Res 1984; 44: 502937.
  • 3
    Kees UR, Ford J, Dawson VM, Piall E, Aherne GW. Development of resistance to 1-β-d-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines. Cancer Res 1989; 49: 301519.
  • 4
    Tsuruo T, Naganuma K, Iida H et al . Establishment of human KB cells resistant to 1-β-d-arabinofuranosylcytosine, and mechanisms of cellular resistance in isolated clones. Gann 1984; 75: 6908.
  • 5
    Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-β-d-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992; 52: 238993.
  • 6
    Obata T, Endo Y, Tanaka M, Matsuda A, Sasaki T. Development and biochemical characterization of a 2′-C-cyano-2′-deoxy-1-β-d-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080. Cancer Lett 1998; 123: 5361.
  • 7
    Obata T, Endo Y, Tanaka M, Uchida H, Matsuda A, Sasaki T. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn J Cancer Res 2001; 92: 7938.
  • 8
    Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Medical Chem 1996; 39: 500511.
  • 9
    Kanda H, Takatori S, Matsuda A et al . Cytotoxic mechanisms of new antitumor nucleoside analogues, 3′-ethynylcytidine (ECyd) and 3′-ethynyluridine (EUrd). Nucleic Acids Symp Ser 1997; (37): 1378.
  • 10
    Tabata S, Tanaka M, Endo Y, Obata T, Matsuda A, Sasaki T. Anti-tumor mechanisms of 3′-ethynyluridine and 3′-ethynylcytidine as RNA synthesis inhibitors: development and characterization of 3′-ethynyluridine-resistant cells. Cancer Lett 1997; 116: 22531.
  • 11
    Matsuda A, Fukushima M, Wataya Y, Sasaki T. A new antitumor nucleoside, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine (ECyd), is a potent inhibitor of RNA synthesis. Nucleosides Nucleotides 1999; 18: 81114.
  • 12
    Azuma A, Matsuda A, Sasaki T, Fukushima M. 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine (ECyd, TAS-106) 1: antitumor effect and mechanism of action. Nucleosides Nucleotides Nucl Acids 2001; 20: 60919.
  • 13
    Shimamoto Y, Fujioka A, Kazuno H et al . Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine. Jpn J Cancer Res 2001; 92: 34351.
  • 14
    Koizumi K, Shimamoto Y, Azuma A et al . Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. Int J Mol Med 2001; 8: 2738.
  • 15
    Murata D, Endo Y, Obata T et al . A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3′-ethynyl nucleosides. Drug Metab Dispos 2004; 32: 117882.
  • 16
    Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol 2001; 18: 5363.
  • 17
    Galmarini CM, Thomas X, Calvo F et al . Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 2002; 26: 6219.
  • 18
    Obata T, Endo Y, Murata D, Sakamoto K, Sasaki T. The molecular targets of antitumor 2′-deoxycytidine analogues. Curr Drug Targets 2003; 4: 30513.
  • 19
    Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95: 7537.
  • 20
    Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 73543.
  • 21
    Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004; 5: 6384.
  • 22
    Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M et al . Cell entry and export of nucleoside analogues. Virus Res 2005; 107: 15164.
  • 23
    Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 1999; 5: 21624.
  • 24
    Cass CE, Young JD, Baldwin SA et al . Nucleoside transporters of mammalian cells. Pharm Biotechnol 1999; 12: 31352.
  • 25
    Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447: 72834.
  • 26
    Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 1286: 15381.
  • 27
    Mangravite LM, Badagnani I, Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 2003; 479: 26981.
  • 28
    Lai Y, Bakken AH, Unadkat JD. Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin–Darby canine kidney cells: Localization and vectorial transport studies. J Biol Chem 2002; 277: 37 71117.
  • 29
    Baldwin SA, Yao SY, Hyde RJ et al . Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005; 280: 15 8807.
  • 30
    Barnes K, Dobrzynski H, Foppolo S et al . Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 2006; 99: 51019.
  • 31
    Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 2004; 279: 50 0429.
  • 32
    Matsuda A, Nakajima Y, Azuma A, Tanaka M, Sasaki T. Nucleosides and nucleotides. 100. 2′-C-cyano-2′-deoxy-1-β-d-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside. J Med Chem 1991; 34: 291719.
  • 33
    Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 93642.
  • 34
    Tanaka M, Matsuda A, Terao T, Sasaki T. Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β-d-arabinofuranosylcytosine (CNDAC) against murine and human tumors. Cancer Lett 1992; 64: 6774.